Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing - PubMed (original) (raw)
Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing
G A Rodrigues et al. Mol Cell Biol. 1991 Jun.
Abstract
The met proto-oncogene is a member of the family of tyrosine kinase growth factor receptors. We describe the isolation and characterization of a cDNA clone (pOK) for the met receptor from a gastric carcinoma cell line. This clone differs from the published cDNA clone by the absence of 54 bp predicted to encode 18 amino acids in the extracellular domain. The pOK cDNA corresponds to the most abundant met RNA species of 8 kb expressed in human cell lines and tissue, and we show that there are in fact two 8-kb met receptor tyrosine kinase (RTK) isoforms that are generated by alternative splicing. This newly described met isoform when transiently expressed in COS cells encodes a protein of 190 kDa which corresponds in size to the p190 met alpha beta heterodimer expressed in human cell lines. Furthermore, we show that the 190-kDa product of pOK consists of the 140-kDa met beta subunit associated with the 50-kDa met alpha subunit. This finding suggests that both the alpha and beta met chains are encoded by this construct and confirms the hypothesis that a single chain precursor is cleaved to produce both subunits of met. In contrast, the previously characterized met isoform corresponds to a minor met RNA species and encodes a protein of 170 kDa that is not cleaved yet is processed in a manner that allows cell surface expression. Both met RTK isoforms are autophosphorylated in the in vitro kinase assay. These results suggest that different isoforms of the met RTK may have distinct biological activities.
Similar articles
- Isoforms of the met receptor tyrosine kinase.
Rodrigues GA, Park M. Rodrigues GA, et al. EXS. 1993;65:167-79. EXS. 1993. PMID: 8380736 Review. - c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase.
Katoh M, Yazaki Y, Sugimura T, Terada M. Katoh M, et al. Biochem Biophys Res Commun. 1993 May 14;192(3):1189-97. doi: 10.1006/bbrc.1993.1542. Biochem Biophys Res Commun. 1993. PMID: 7685162 - Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor).
Mondino A, Giordano S, Comoglio PM. Mondino A, et al. Mol Cell Biol. 1991 Dec;11(12):6084-92. doi: 10.1128/mcb.11.12.6084-6092.1991. Mol Cell Biol. 1991. PMID: 1658624 Free PMC article. - A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells.
Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al. Scott GK, et al. Mol Cell Biol. 1993 Apr;13(4):2247-57. doi: 10.1128/mcb.13.4.2247-2257.1993. Mol Cell Biol. 1993. PMID: 8096058 Free PMC article.
Cited by
- Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.
Kim HJ. Kim HJ. Medicina (Kaunas). 2022 May 11;58(5):649. doi: 10.3390/medicina58050649. Medicina (Kaunas). 2022. PMID: 35630066 Free PMC article. Review. - Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, Park M. Stern YE, et al. Cell Mol Life Sci. 2022 Mar 5;79(3):178. doi: 10.1007/s00018-022-04149-w. Cell Mol Life Sci. 2022. PMID: 35249128 Free PMC article. - CLIP-170 spatially modulates receptor tyrosine kinase recycling to coordinate cell migration.
Zaoui K, Duhamel S, Parachoniak CA, Park M. Zaoui K, et al. Traffic. 2019 Mar;20(3):187-201. doi: 10.1111/tra.12629. Epub 2019 Jan 15. Traffic. 2019. PMID: 30537020 Free PMC article. - Physiological Signaling and Structure of the HGF Receptor MET.
Baldanzi G, Graziani A. Baldanzi G, et al. Biomedicines. 2014 Dec 31;3(1):1-31. doi: 10.3390/biomedicines3010001. Biomedicines. 2014. PMID: 28536396 Free PMC article. Review. - Development of antibody-based c-Met inhibitors for targeted cancer therapy.
Lee D, Sung ES, Ahn JH, An S, Huh J, You WK. Lee D, et al. Immunotargets Ther. 2015 Feb 9;4:35-44. doi: 10.2147/ITT.S37409. eCollection 2015. Immunotargets Ther. 2015. PMID: 27471710 Free PMC article. Review.
References
- EMBO J. 1990 Aug;9(8):2409-13 - PubMed
- FEBS Lett. 1986 Dec 15;209(2):357-61 - PubMed
- Mol Cell Biol. 1990 Jun;10(6):2973-82 - PubMed
- Mol Cell Biol. 1990 Aug;10(8):4202-10 - PubMed
- Nucleic Acids Res. 1983 Mar 11;11(5):1295-308 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous